転移性前立腺癌と新たに診断された男性における細胞減量根治的前立腺摘除術の治療効果

基本情報

NCT ID: NCT03456843
ステータス: 実施中（募集終了）
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 190
治験依頼者名: Yale University

概要

This randomized phase II trial studies how well surgical removal of the prostate and antiandrogen therapy with or without docetaxel work in treating men with newly diagnosed prostate cancer that has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Antiandrogen therapy may lessen the amount of androgens made by the body. Drugs used in chemotherapy, such as docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Surgery, antiandrogen therapy and docetaxel may work better in treating participants with prostate cancer.

対象疾患

Stage IV Prostate Adenocarcinoma AJCC v7

介入

Antiandrogen Therapy(DRUG)

Docetaxel(DRUG)

Laboratory Biomarker Analysis(OTHER)

Quality-of-Life Assessment(PROCEDURE)

Questionnaire Administration(OTHER)

Radical Prostatectomy(PROCEDURE)

依頼者（Sponsor）

National Cancer Institute (Nci)(NIH)

Yale University(OTHER)

実施施設 (4)

Juntendo University

Tokyo, Japan

医療法人　あきた耳鼻咽喉科クリニック

Akita, Japan

Juntendo University

Tokyo, Japan

近畿大学東洋医学研究所附属診療所

Ōsaka-sayama, Osaka, Japan